Dr. Postow Discusses New Targets in Melanoma

Video

In Partnership With:

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses new targets in melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses new targets in melanoma.

In the treatment of patients with melanoma, well known targets such as CTLA4 and PD-1 have been at the forefront of research. Ipilimumab (Yervoy) has been shown to successfully target CTLA-4, while pembrolizumab (Keytruda) and nivolumab (Opdivo) target PD-1. But, Postow says that new immunotherapy targets are emerging in 2018.

IDO and LAG-3 both have very interesting emerging data in melanoma, says Postow. There are also completely new targets that act through various mechanisms, such as inhibiting metabolism in the tumor microenvironment, he adds.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,